Bitter infighting leads to a breakup in ALS advocacy group; Biogen CEO faces his first crisis

Taking stock of the drug industry, from the lab to the medicine chest

June 14, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

John Blanding/The Boston Globe via AP STAT+ | Bitter infighting leads 15 chapters to break away from leading ALS advocacy group The ALS Association has settled a lawsuit filed by 15 chapters that will now break away to form an alternative organization. By Ed Silverman STAT+ | Muzzled for years, vindicated MIT professor says fraud investigation into his lab did lasting damage Ram Sasisekharan had his work sidelined and his team decimated following allegations of research fraud. But he couldn't say a thing. By Damian Garde STAT+ | Biogen's boardroom scandal saddles CEO with first crisis The nomination of a biotech executive who is the mother of a director's child has created a headache for CEO Chris Viehbacher. By Damian Garde and Adam Feuerstein Elise Amendola/AP STAT+ | Health insurance stocks tumble after UnitedHealth says Medicare enrollees are getting more care A top UnitedHealth executive said it's noticed "a meaningfully higher number" of outpatient visits among Medicare patients lately. By Bob Herman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser